Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)

NCT00386685 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00386685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00386685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2006
Completion date
January 31, 2011
Enrollment
51 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms